Project Name: Pharmacist led Lipid management model of care in North East London (NEL) Collaborative Working

Project Summary:

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) in response to the needs of the CW Partner. This will be done with the hiring of Specialist Pharmacist who will optimise lipid therapy for patients in North East London (NEL) and will support local PCN pharmacists across the 7 boroughs of NEL (see appendix 1 for list of PCN’s in NEL) in their efforts to optimise therapy for patients in Borough by Borough approach. Complex patients will be escalated to a newly created MDT for review.

The CWP will be led by a Consultant Pharmacist & Head of Pharmacy alongside a multi-disciplinary team; including Clinical Pharmacist, aiming to achieve:

  1. Identification of sub-optimally treated ASCVD patients who are not achieving lipid levels as specified in local guidelines
  2. Identification of ASCVD patients who have previously not tolerated or refused alternative lipid modification therapies  
  3. Review of treatment options and decision on next steps in collaboration with ASCVD patients with Patients at the highest risk to be prioritised for review (defined by the NHS partner as  Adult patients who have had an IHD,PAD or Stroke/TIA and are not on a statin therapy and  adult patients with a  sub-optimal non-HDL > 2.5mmol/L despite maximal statin therapy. Cohorts defined by using the UCLP measures.)
  4. Counsel and optimise ASCVD patients where appropriate  
  5. Early identification of at-risk patients who have not had intervention in their health and wellbeing 
  6. Identification of ASCVD patients, following risk assessment review, of ASCVD patients who are sub-optimally treated  
  7. On-going ASCVD patients support and annual review to ensure CVD outcomes improve equitably

Planned Milestones:

Barts Table

Expected Benefits:

Anticipated benefits for patients

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.   
  • Enhanced experience around ASCVD with ongoing management of the condition.   
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events  
  • Easier access to lipid management care closer to home in the Primary Care setting
  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, leveling health inequalities within the PCN.

Anticipated benefits for the NHS

  • Increased proportion of ASCVD patients reviewed by primary care   
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home  
  • Reduction in ASCVD referral rates to secondary care  
  • Increased proportion of patients receiving guideline-directed pharmacotherapy  
  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care   
  • Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES 

Anticipated Benefits for Novartis

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine  
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities    
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation  

Start Date & Duration: October 2022 – December 2024 (2 years 2 months)